We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 1, 2009
Last Update Posted: June 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Hope Pharmaceuticals
The purpose of the study is to examine the safety of a 14 day infusion of sodium nitrite, and to study the pharmacokinetics of nitrite, during a 14 day infusion in patients with ruptured cerebral aneurysms.

Condition Intervention Phase
Subarachnoid Hemorrhage Drug: Sodium nitrite Drug: Saline Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Safety and Pharmacokinetic Evaluation of Sodium Nitrite Injection for the Prevention of Post-Subarachnoid Hemorrhage Induced Vasospasm

Resource links provided by NLM:

Further study details as provided by Hope Pharmaceuticals:

Primary Outcome Measures:
  • Mean Plasma Nitrite Concentration (Micromol/L) [ Time Frame: multiple time points up to the end of day 14 ]
    Samples for pharmacokinetic analysis were collected from subjects treated with sodium nitrite at -15, -5, 0, 10, 30, 60, and 90 minutes after starting nitrite infusion and then at 2, 4, 6, 8, 12, 24, and every 24 hours after starting nitrite infusion. The sample at the time of starting the infusion was considered to be the time 0 sample. On study day 14 additional blood samples were collected at 0, 10, 30, 60, and 90 minutes and at 2, 4, 6, 8, and 12 hours after stopping nitrite infusion. Blood samples were analyzed for nitrite levels using mass spectroscopy.

Secondary Outcome Measures:
  • Safety of a 14 Day Infusion of Sodium Nitrite [ Time Frame: 14 days ]
  • Efficacy of 14 Day Infusion of Sodium Nitrite [ Time Frame: 14 days ]

Enrollment: 19
Study Start Date: April 2010
Study Completion Date: August 2012
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nitrite
Continuous intravenous infusion of Sodium Nitrite
Drug: Sodium nitrite
14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
Other Name: Sodium Nitrite Injection NDC 60267-311-10
Placebo Comparator: Vehicle control
Continuous intravenous infusion of saline
Drug: Saline
14 day continuous infusion of a vehicle control infusion
Other Name: Sterile saline

Detailed Description:

Intravenous sodium nitrite has been shown to prevent and to reverse cerebral vasospasm in a primate model of subarachnoid hemorrhage (SAH). This was a Phase IIA dose escalation study of sodium nitrite to determine its safety in patients with aneurysmal SAH and to establish its pharmacokinetics during a 14 day infusion.

Sodium nitrite was delivered intravenously for 14 days in 18 patients with SAH from a ruptured cerebral aneurysm using a dose escalation scheme in three cohorts of 6 patients each (3 nitrite, 3 saline), with a maximum dose of 64 nmol/min/kg. Sodium nitrite blood levels were frequently sampled and measured using mass spectroscopy and blood methemoglobin levels were continuously monitored using a pulse oximeter.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ruptured cerebral aneurysm

Exclusion Criteria:

  • Pregnancy, sickle cell disease, G6PD deficiency, anticoagulant therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00873015

United States, Virginia
University of Virginia Health System Medical Center
Charlottesville, Virginia, United States, 22903
Sponsors and Collaborators
Hope Pharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Edward Oldfield, MD University of Virginia
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hope Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00873015     History of Changes
Other Study ID Numbers: 14024
1R44NS063485-01 ( U.S. NIH Grant/Contract )
First Submitted: March 31, 2009
First Posted: April 1, 2009
Results First Submitted: January 26, 2013
Results First Posted: July 16, 2013
Last Update Posted: June 7, 2017
Last Verified: May 2017

Keywords provided by Hope Pharmaceuticals:
Cerebral aneurysm
Subarachnoid hemorrhage

Additional relevant MeSH terms:
Subarachnoid Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases